Ladiratuzumab | MedChemExpress (MCE)
Ladiratuzumab (hLIV22) is an anti-LIV-1/ZIP6 humanized monoclonal antibody. Ladiratuzumab, conjugated with the microtubule disrupting agent, MMAE (HY-15162) to compose SGN-LIV1A, an antibody-drug conjugate (ADC). Ladiratuzumab can be used for research of breast cancer[1][2].
| Trivial name | Ladiratuzumab |
| Catalog Number | HY-P99682 |
| Alternative Name(s) | hLIV22 |
| Research Area | Cancer |
| CAS# | 1629760-28-6 |
| Purity | ≥98.00% |
| SMILES | [Ladiratuzumab] |
| Size | 5 mg |
| Supplier Page | https://www.medchemexpress.com/ladiratuzumab.html |